血清可溶性Fas及FasL水平与膀胱癌病理特征的关系

Relationships of Serum Soluble Fas and Soluble FasL Levels to Pathological Characters of Bladder Carcinoma

目的探讨血清可溶性Fas(sFas)及FasL(sFasL)含量变化与膀胱癌病理特征的关系,以确定血清sFas及sFasL含量检测在临床上的应用价值。方法采用酶联免疫吸附试验(Elisa)定量检测78例膀胱癌患者(膀胱癌组,浅表性膀胱癌54例,浸润性膀胱癌24例;G1期20例,G2期39例,G3期19例)术前、术后和30例健康体检者(对照组)血清中sFas和sFasL的水平。观察血清sFas和sFasL含量的变化与膀胱癌病理特征的关系。结果膀胱癌组术前血清中sFas和sFasL含量分别为(18.53±1.74)、(13.46±1.57)μg·L-1,明显高于术后及对照组[(7.03±1.54)、(4.38±1.23)μg·L-1及(5.98±1.36)、(3.42±1.03)μg·L-1](均P<0.05)。膀胱癌组术后血清sFas和sFasL含量与对照组比较差异均无统计学意义(均P>0.05)。浸润性膀胱癌患者血清中sFas和sFasL含量均显著高于浅表性膀胱癌患者(均P<0.05);膀胱癌G3期患者血清中sFas和sFasL含量均显著高于G1、G2期患者(均P<0.05)。结论血清中sFas和sFasL水平可能成为膀胱癌患者病理特征判断以及治疗过程中疗效观察的指标。

Objective To explore the relationships of serum soluble Fas （sFas）and soluble FasL （sFasL）levels to pathological characters of bladder cancer,and to identify the clinical value of the detection of serum sFas and sFasL levels.Methods Serum sFas and sFasL levels were de-tected by ELISA in 30 healthy subjects （control group）and 78 patients with bladder cancer （bladder cancer group,54 cases of superficial bladder cancer and 24 cases of invasive bladder canc-er;20 cases of G1 tumors,39 cases of G2 tumors and 19 cases of G3 tumors）.The relationships of serum sFas and sFasL levels to pathological characters of bladder cancer were analyzed.Results In patients with bladder cancer,serum sFas and sFasL levels measured before operation were sig-nificantly higher than those measured after operation [（18.53±1.74）and （13.46±1.57）μg· L-1 vs （7.03±1.54）and （4.38±1.23）μg·L-1 ,respectively;P 〈0.05].Before operation,ser-um sFas and sFasL levels in bladder cancer group were significantly higher than those in control group [（18.53±1.74）and （13.46 ± 1.57）μg·L-1 vs （5.98± 1.36）and （3.42 ± 1.03）μg· L-1 ,respectively;P 〈0.05].There were no significant differences in serum sFas and sFasL levels between bladder cancer group and control group after operation （P 〉 0.05）.Serum sFas and sFasL levels in patients with invasive bladder cancer were significantly higher than those in pa-tients with superficial bladder cancer （P 〈0.05）.Serum sFas and sFasL levels in patients with G3 tumors were significantly higher than those in patients with G1 or G2 tumors （P 〈0.05）.Conclu-sion Serum sFas and sFasL levels may be used to identify the pathological characters and to as-sess the curative efficacy in patients with bladder cancer.